Project Grant R01CA309039
Award Date 4/1/26
Completion Date 3/31/31
Dollars Obligated $681K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Regents of the University of California, San Francisco a $680,598 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective September 1, 2025, with a completion date of August 31, 2030. The award supports fundamental research focused on decoding the Cullin-5 (CUL5) E3 ubiquitin ligase complex to engineer therapeutic T cells with enhanced durability and sustained effector function. The project...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $421,685 Project Grant to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) for research activities spanning August 8, 2025 through July 31, 2027. This award funds a discovery-focused research initiative investigating functional immune niches within the tumor microenvironment (TME) that support effective cancer immunotherapy responses. The primary deliverable...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $375,150 to The Regents of the University of California, San Francisco under the Cancer Treatment Research program (CFDA 93.395) to fund a five-year research initiative (September 1, 2025 – August 31, 2030). The research addresses innate resistance mechanisms to KRAS inhibitors in cancer treatment, focusing on the role of the RhoA-ROCK-Myosin IIA cytoskeletal axis in promoting drug-tolerant persister...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $658,722 Project Grant to The Regents of the University of California, San Francisco (UCSF) under the Cancer Treatment Research program (CFDA 93.395), effective March 12, 2026, with a completion date of February 28, 2031. This research initiative investigates the mechanisms by which TERT promoter mutations enable tumor cell immortality across multiple cancer types. The project will develop experimental tools and...
- Federal Project Grant Award Summary The University of California, San Francisco received a $677,787 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective August 26, 2025, with a completion date of July 31, 2030. The award funds research to identify and characterize Aire-expressing tumor-associated macrophages (AIRE+ TAMs) as novel mediators of tumor immune evasion and to develop therapeutic strategies targeting this...
- Federal Grant Award Summary The National Cancer Institute awarded The Washington University a Project Grant totaling $399,829 under the Cancer Treatment Research program (CFDA 93.395) for the period April 1, 2026 through March 31, 2028. The award funds research focused on rational design of next-generation engineered T cells to enhance cancer immunotherapy by addressing the critical challenge of limited T cell persistence. The project employs structure-informed protein design to optimize 4-1BB...
- Federal Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research a $452,540 Project Grant under the Cancer Biology Research program (CFDA 93.396) for the period of May 1, 2026 through April 30, 2028. This award supports fundamental research investigating the innate and adaptive determinants of cytokine release syndrome (CRS) following chimeric antigen receptor (CAR) T-cell therapy. The research aims to elucidate the molecular mechanisms underlying...
- Federal Grant Award Summary The National Cancer Institute awarded a $710,361 Project Grant under the Cancer Biology Research program (CFDA 93.396) to J. David Gladstone Institutes, effective August 1, 2025, through May 31, 2030. This award funds the development of a spatial profiling-based immune hub perturbation platform designed to improve immunotherapy efficacy in colorectal cancer (CRC). The research addresses a critical gap in preclinical modeling by creating experimental frameworks that...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $618,928 Project Grant to The Regents of the University of California, doing business as University of California, Berkeley, under the Cancer Biology Research program (CFDA 93.396) on June 9, 2025. The award funds a five-year research initiative through May 31, 2030, investigating the immunosuppressive mechanisms of intratumoral regulatory T cells (Tregs) to advance immune-based cancer therapies. The research...
- Federal Grant Award Summary The National Cancer Institute awarded a $663,340 Project Grant to the University of California, Berkeley on August 27, 2025, under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on regulatory T cell-mediated suppression of tumor elimination. The research will elucidate mechanisms by which local ablation of intra-tumoral regulatory T cells (IT-Tregs) mobilizes natural killer (NK) cells and CD4 T cells to control tumors that have...